

IASLC 2022 World Conference on Lung Cancer | Vienna, Austria


# Novel anti-PD-(L)1/anti-TIGIT Combinations: Are these Breaking New Ground in NSCLC?

Live

Saturday August 6<sup>th</sup>  
12:00–13:00 (CEST)  
Hall C1

On Demand

August 7<sup>th</sup>–November 9<sup>th</sup>



## Learning Objectives

- Highlight the unmet needs in first-line treatment for patients with locally advanced and metastatic NSCLC without actionable oncogenic driver alterations
- Provide an overview of the biological and clinical rationale for PD-(L)1/TIGIT inhibitor combinations in NSCLC
- Discuss the clinical development of emerging PD-(L)1/TIGIT inhibitor combinations in patients with locally advanced and metastatic NSCLC, and where these combinations may best fit in the NSCLC treatment landscape



**Barbara Melosky (Chair)**

Professor of Medicine, University of British Columbia, Canada. Medical Oncologist, BC Cancer Center, Vancouver, Canada



**Riyaz Shah**

Consultant Thoracic Medical Oncologist, The Kent Oncology Centre, Maidstone, UK



**Giorgio Scagliotti**

Professor of Medical Oncology, University of Torino, Italy. Chief of the Division of Medical Oncology, S. Luigi Hospital, Torino, Italy

## Agenda Topics

Welcome and Program Overview

Laying the Foundation: The need to go further with IO in advanced NSCLC

Building Upward: Emerging anti-PD-(L)1/anti-TIGIT combinations in NSCLC

Panel Discussion: How to break new ground with anti-TIGIT combinations

Q&A Session

## Speakers

Barbara Melosky

Riyaz Shah

Giorgio Scagliotti

**Chair:**  
Barbara Melosky

**Discussants:**  
Riyaz Shah &  
Giorgio Scagliotti

**Chair:**  
Barbara Melosky

**This program and/or material was developed for use outside of the US, is intended for non-US HCPs, and is to be used in accordance with local laws and regulations**

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.